EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Chemokine CXCL9, a marker of inflammaging, is associated with changes of muscle strength and mortality in older men

Da Hea Seo, Maripat Corr, Sheena Patel, Li-Yung Lui, Jane A Cauley, Daniel Evans, Theresa Mau, Nancy E Lane

Osteoporosis International · 2024-10 · 35 (10) · 1789-1796

DOI: 10.1007/s00198-024-07160-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Osteoporosis International, online erschienen am 04.07.2024. Verfasst von Da Hea Seo und 7 weiteren Autor:innen. Beteiligte Einrichtung: San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, CA, USA. Hauptthemen laut MEDLINE: Muscle Strength, Osteoporotic Fractures, Biomarkers, Bone Density. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAMS NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our study examined associations of the CXC motif chemokine ligand 9 (CXCL9), a pro-inflammatory protein implicated in age-related inflammation, with musculoskeletal function in elderly men. We found in certain outcomes both cross-sectional and longitudinal significant associations of CXCL9 with poorer musculoskeletal function and increased mortality in older men. This requires further investigation. PURPOSE: We aim to determine the relationship of (CXCL9), a pro-inflammatory protein implicated in age-related inflammation, with both cross-sectional and longitudinal musculoskeletal outcomes and mortality in older men. METHODS: A random sample from the Osteoporotic Fractures in Men (MrOS) Study cohort (N = 300) was chosen for study subjects that had attended the third and fourth clinic visits, and data was available for major musculoskeletal outcomes (6 m walking speed, chair stands), hip bone mineral density (BMD), major osteoporotic fracture, mortality, and serum inflammatory markers. Serum levels of CXCL9 were measured by ELISA, and the associations with musculoskeletal outcomes were assessed by linear regression and fractures and mortality with Cox proportional hazards models. RESULTS: The mean CXCL9 level of study participants (79.1 ± 5.3 years) was 196.9 ± 135.2 pg/ml. There were significant differences for 6 m walking speed, chair stands, physical activity scores, and history of falls in the past year across the quartiles of CXCL9. However, higher CXCL9 was only significantly associated with changes in chair stands (β = - 1.098, p < 0.001) even after adjustment for multiple covariates. No significant associations were observed between CXCL9 and major osteoporotic fracture or hip BMD changes. The risk of mortality increased with increasing CXCL9 (hazard ratio quartile (Q)4 vs Q1 1.98, 95% confidence interval 1.25-3.14; p for trend < 0.001). CONCLUSIONS: Greater serum levels of CXCL9 were significantly associated with a decline in chair stands and increased mortality. Additional studies with a larger sample size are needed to confirm our findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscle StrengthOsteoporotic FracturesBiomarkersBone DensityChemokine CXCL9HumansMaleAgedCross-Sectional StudiesAged, 80 and overAgingLongitudinal StudiesWalking SpeedInflammationHip Joint

Stichwörter der Autor:innen

CytokinesFunctional performanceMortalityOsteoporotic fractures

Substanzen

BiomarkersChemokine CXCL9CXCL9 protein, human

Autor:innen und Institutionen

  • San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, CA, USA.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha University College of Medicine, Incheon, Republic of Korea.
  • Department of Medicine, University of California, San Diego, CA, USA.
  • Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
  • Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
  • Department of Medicine and Rheumatology, University of California, Davis, CA, USA. nelane@ucdavis.edu.

Förderung

  • NIAMS NIH HHS
  • NIA NIH HHS

Zitieren

APA

Seo, D. H., Corr, M., Patel, S., Lui, L. Y., Cauley, J. A., Evans, D., Mau, T., & Lane, N. E. (2024). Chemokine CXCL9, a marker of inflammaging, is associated with changes of muscle strength and mortality in older men. Osteoporosis International, 35(10), 1789-1796. https://doi.org/10.1007/s00198-024-07160-y

Vancouver

Seo DH, Corr M, Patel S, Lui LY, Cauley JA, Evans D, et al. Chemokine CXCL9, a marker of inflammaging, is associated with changes of muscle strength and mortality in older men. Osteoporosis International. 2024;35(10):1789-1796. doi:10.1007/s00198-024-07160-y

BibTeX
@article{Seo2024,
  author = {Seo, Da Hea and Corr, Maripat and Patel, Sheena and Lui, Li-Yung and Cauley, Jane A and Evans, Daniel and Mau, Theresa and Lane, Nancy E},
  title = {Chemokine CXCL9, a marker of inflammaging, is associated with changes of muscle strength and mortality in older men},
  journal = {Osteoporosis International},
  year = {2024},
  volume = {35},
  number = {10},
  pages = {1789--1796},
  doi = {10.1007/s00198-024-07160-y}
}
Kostenlos starten →